Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SLC7A11 | Q9UPY5 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15368089 | 0.90 | HIF1A (0.55) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL1593317 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL12610177 | 0.84 | HIF1A (0.60) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL15368092 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL15810557 | 0.75 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL15368088 | 0.75 | HIF1A (0.65) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL1593252 | 0.75 | HIF1A (0.60) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL1593420 | 0.73 | HIF1A (0.50) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL18306594 | 0.73 | HIF1A (0.58) | ALDH1A1SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL14464267 | 0.72 | PDE7A (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | MKI67, MCL1, HCCS | ALDH1A1 365/4885SMN1; SMN2 2391/4885HIF1A 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.